Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 1/2020

Open Access 01-01-2020 | Nephrectomy | Kidney Diseases (G Ciancio, Section Editor)

Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft

Authors: Hannah Warren, Jonathon Olsburgh

Published in: Current Urology Reports | Issue 1/2020

Login to get access

Abstract

Purpose of Review

Renal masses in the kidney graft pose an important clinical dilemma, balancing graft function against the need for cancer control.

Recent Findings

Donor origin cancers in the renal graft can be classified as ‘donor transmitted’ or ‘donor derived’. The landmark TracerX Renal changed our understanding of renal cell carcinoma oncogenesis, demonstrating that key mutations in childhood lead to clinically apparent tumours in later life. Identified pre-operatively, contemporary evidence suggests that masses excised prior to transplantation result in acceptable oncologic safety and graft function. Identified post-operatively management mirrors that for a mass in a solitary kidney in the non-transplant population, with focus on a nephron-sparing approach.

Summary

With growing number of kidney transplants each year, ageing donors, and increasing graft survival, masses in the renal graft are likely to become a more prevalent clinical conundrum.
Literature
1.
NHS Blood and Transplant. Organ donation and transplantation: activity report 2017/18. 2018.
2.
Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors - unavoidable but low risk. Transplantation. 2012;94(12):1200–7.CrossRef
3.
Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74(3):358–62.CrossRef
4.
British Transplantation Society. Guidelines for living donor kidney transplantation. Fourth Edition [Internet]. 2018. Available from: www.​bts.​org.​uk
5.
Ploussard G, Chambade D, Meria P, Gaudez F, Tariel E, Verine J, et al. Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort. Br J Urol Int. 2011:195–9.
6.
Tillou X, Doerfler A, Collon S, Kleinclauss F, Patard JJ, Badet L, et al. De novo kidney graft tumors: results from a multicentric retrospective national study. Am J Transplant. 2012;12(12):3308–15.CrossRef
7.
Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428–37.CrossRef
8.
Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F, et al. Intrarenal resistive index after renal transplantation. N Engl J Med. 2013;369(19):1797–806.CrossRef
9.
Breda A, Budde K, Figueiredo A, Garcia E, Olsburgh J, Regele H, et al. EAU guidelines on renal transplantation. 2019.
10.
Kidney Disease Improving Global Outcomes. KDIGO Clinical Practice Guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Supplement 3):S131–55.
11.
Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11:S1–86.PubMed
12.
The Renal Association, British Transplantation Society. Clinical practice guideline in post-operative care in the kidney transplant recipient. 2017.
13.
Knoll GA, Blydt-Hansen TD, Campbell P, Cantarovich M, Cole E, Fairhead T, et al. Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis. 2010;56(2):219–46.CrossRef
14.
Heemann U, Abramowicz D, Spasovski G, Vanholder R. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant. 2011;26(7):2099–106.CrossRef
15.
16.
Nalesnik MA, Woodle ES, DiMaio JM, Vasudev B, Teperman LW, Covington S, et al. Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant. 2011;11(6):1140–7.CrossRef
17.
Nicol DL, Preston JM, Wall DR, Griffin AD, Campbell SB, Isbel NM, et al. Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. BJU Int. 2008;102(2):188–92.CrossRef
18.
Ogawa Y, Kobayashi T, Shiroma S, Kojima K, Mannami R, Mannami M, et al. Restored kidney transplant using kidneys affected by small tumors: outcomes and lessons learned. Transplant International. 2012; 239.
19.
Mannami M, Mannami R, Mitsuhata N, Nishi M, Tsutsumi Y, Nanba K, et al. Last resort for renal transplant recipients, “restored kidneys” from living donors/patients. Am J Transplant. 2008;8(4):811–8.CrossRef
20.
• Hevia V, Hassan Zakri R, Fraser Taylor C, Bruins HM, Boissier R, Lledo E, et al. Effectiveness and harms of using kidneys with small renal tumors from deceased or living donors as a source of renal transplantation: a systematic review. Eur Urol Focus. 2019;5(3):508–17 A systematic review of 109 kidneys with excision of small renal masses prior to transplantation demonstrating similar functional outcome to other donor kidneys, and only one local recurrence.
21.
Brook NR, Gibbons N, Johnson DW, Nicol DL. Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients. Transpl Int. 2010;23(5):476–83.CrossRef
22.
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Montes SFP, et al. European Association of Urology Guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.CrossRef
23.
Gervais DA, Giambarresi L, Lane BR, Campbell S, Davis BJ, Bass EB, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520–9.CrossRef
24.
• Tillou X, Guleryuz K, Collon S, Doer A. Renal cell carcinoma in functional renal graft: toward ablative treatments. Transplant Rev. 2016;30:20–6 Literature review of 201 functional graft renal cell carcinomas reporting tumour histology, and management with tendency to a nephron sparing approaches.
25.
Chen KT, Olszanski A, Farma JM. Donor transmission of melanoma following renal transplant. Case Rep Transplant. 2012;2012:1–3.
26.
Chiu HF, Wen MC, Li JR, Ho HC, Shu KH. Successful treatment with sirolimus for an angiomyolipoma mimicking renal cell carcinoma in a transplanted kidney. Transpl Int. 2015;28(9):1116–20.CrossRef
27.
•• Griffith JJ, Amin KA, Waingankar N, Lerner S, Delaney V, Ames S, et al. Solid renal masses in transplanted allograft kidneys : a closer look at the epidemiology and management. Am J Transplant. 2017;17:2775–81 A PRISMA methodology literature review reporting epidemiology and management of 174 small renal masses identified in transplant kidney grafts.
28.
Pagano D, di Francesco F, Rosa L, Nwaiwu CA, Li Petri S, Gruttadauria S. Oncocytoma managed by active surveillance in a transplant allograft kidney: a case report. World J Surg Oncol. 2018;16(1):2–5.CrossRef
29.
Villanueva LAA, Knust M, Quintella L, Suassuna JHR, Araújo NC. Renal oncocytoma in a kidney transplant patient: the imaging features on contrast-enhanced ultrasonography (CEUS): a case report. Brazilian J Nephrol. 2018;40(1):86–90.CrossRef
30.
Steiner MS, Goldman SM, Fishman EK, Marshall FF. The natural history of renal angiomyolipoma. J Urol. 1993;150:1782–6.CrossRef
31.
De Luca S, Terrone C, Rocca RS. Management of renal angiomyolipoma: a report of 53 cases (multiple letters) [3]. BJU Int. 1999;83:215–8.CrossRef
32.
Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh urology. Eleventh Edition. 2016. p1306.
33.
Davies DM, De Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071–81.CrossRef
34.
Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One. 2011;6(9).
35.
Engels E, Pfeiffer R, Fraumeni J, Kasiske B, Israni A, Snyder J, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA J Am Med Assoc. 2011;306(17):1891–901.CrossRef
36.
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–13.CrossRef
37.
Deng FM, Melamed J. Histologic variants of renal cell carcinoma: does tumor type influence outcome? Urol Clin North Am. 2012;39(2):119–32.CrossRef
38.
Gigante M, Neuzillet Y, Patard J-J, Tillou X, Thuret R, Branchereau J, et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int. 2012;110(11b):E570–3.CrossRef
39.
Tickoo SK, de Peralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, et al. Spectrum of epithelial neoplasms in end-stage renal disease. Am J Surg Pathol. 2006;30(2):141–53.CrossRef
40.
•• Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JI, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell. 2018;173(3):581–594.e12 Prospective multicenter study and two validation cohorts assess the genetic evolution and identify genomic drivers of metastatic renal cell carcinoma.
41.
•• Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O’Brien T, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal. Cell. 2018;173(3):611–623.e17 Whole genome sequencing study of 33 clear cell renal cell carcinomas demonstrates that key oncogenic drivers occur as early as late childhood and early adolescence.
42.
Park K, Inoue H, Kim C, Tomoyoshi T. Nephron-sparing surgery for de novo renal cell carcinoma in an allograft kidney: a case report. Int J Urol. 1997;4:611–4.CrossRef
43.
Leppert JT, Hanley J, Wagner TH, Chung BI, Srinivas S, Chertow GM, et al. Utilization of renal mass biopsy in patients with renal cell carcinoma. Urology. 2014;83(4):774–80.CrossRef
44.
Eldred-Evans D, Tay A, Rottenberg G, Pattison J, O’Brien T, Olsburgh J. Zero-ischaemia zero-transfusion transplant kidney partial nephrectomy. 2014.
45.
Tillou X, Guleryuz K, Doerfler A, Bensadoun H, Chambade D, Codas R, et al. Nephron sparing surgery for de novo kidney graft tumor: results from a multicenter national study. Am J Transplant. 2014;14(9):2120–5.CrossRef
46.
Barama A, St-Louis G, Nicolet V, Hadjeres R, Daloze P. Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant. 2005;5(12):3015–8.CrossRef
47.
Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006;6(3):514–22.CrossRef
48.
Javaid MM, Chowdhury S, Henderson A, Olsburgh J. Advanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agent. Clin Nephrol. 2013;79(02):154–60.CrossRef
Metadata
Title
Management of Renal Cell Carcinoma and Other Renal Masses in the Kidney Graft
Authors
Hannah Warren
Jonathon Olsburgh
Publication date
01-01-2020
Publisher
Springer US
Published in
Current Urology Reports / Issue 1/2020
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-020-0959-4

Other articles of this Issue 1/2020

Current Urology Reports 1/2020 Go to the issue

Kidney Diseases (G Ciancio, Section Editor)

Troubleshooting Complex Vascular Cases in the Kidney Transplant Recipient: Vascular Anomalies, Challenging Vessel Diseases, and Procedural Disasters

Kidney Diseases (G Ciancio, Section Editor)

Troubleshooting Complex Vascular Cases in the Kidney Graft: Multiple Vessels, Aneurysms, and Injuries During Harvesting Procedures

Kidney Diseases (G Ciancio, Section Editor)

The Failing Kidney Transplant Allograft. Transplant Nephrectomy: Current State-of-the-Art

Kidney Diseases (G Ciancio, Section Editor)

Pelvic Surgery in the Transplant Recipient: Important Considerations for the Non-transplant Surgeon

Kidney Diseases (G Ciancio, Section Editor)

The Ureter in the Kidney Transplant Setting: Ureteroneocystostomy Surgical Options, Double-J Stent Considerations and Management of Related Complications

Kidney Diseases (G Ciancio, Section Editor)

Kidney Transplantation in Transgender Patients